The spectrum of mutations in MM has been shown to be dominated by mutations in the RAS (43% of patients) and NFκB pathways (17%), and recurrent alterations in genes, including TP53, ATM, and ATR, and secondary translocations into MYC (8q24) that have strong associations with adverse risk [9]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.